The MSA (Master Service Agreement) include a first study work order of SEK 4m in sales from late 202...
Angler Gaming plc (”Angler” eller ”Bolaget”) levererade en kv1 2025-rapport under vår förväntan avse...
After the warrant contribution, Ascelia Pharma is well funded for 2025 with some SEK 80m net cash, w...
Soft Q1 earnings driven by gross margin pressure in the US Weaker USD weighs on estimates, given US-...
Redeye comments on Lytix Biopharma’s first quarter review of 2025.
Redeye states Safello's report came in on the weaker side in a quarter with a challenging backdrop.
Redeye reiterates its fair value range following Dala Energi’s Q1 report that was published last Fri...
Nettoomsättningen för det första kvartalet uppgick till 8,2 MEURO (10,9), vilket motsvarade en minsk...
Portfolio rebalancing and weak market behind PW We lower '25e-'27e EBIT by 31-22% on lower sales We ...
Q1 miss, 2025-27e adj. EBITA cut 4-5% FY guidance kept, we estimate 7% EBITA growth in 2025e Share a...
Sales SEK 54m (ABGSCe 55m), EBIT -4m (ABGSCe -7m) Market conditions remain soft, anticipates weaker ...
Redeye provides a brief summary of Elicera’s Q1'25 report.
Voi, som är VNV Globals näst största innehav, kom med en stark Q1-rapport.
Omsättningen sjönk till 8,2 (10,2) meur, varav PremierGaming stod för 6,7%.
The FDA submission is progressing toward the finish line, as illustrated by the more precise expecte...
Cantargia har investerat i en stor fas -1 studie med CAN10 för att skaffa ett bra underlag inför näs...
1% organic growth (cons 4%) and EBITA -13% vs cons Reiterates 2025 guidance of EBITA 2024, Q1 EBITA ...
Orviglance FDA submission during the summer Good cost control Conf call at 10:00 CEST Recent releva...
Redeye provides an update on Thunderful Group following its Q1 2025 report, which was better than ex...
Redeye updates its estimates after reviewing Fable Media Group’s Q1 report, which was softer than ou...
